Literature DB >> 30413339

Justifying conservative management of CIN2 in women younger than 25 years - A population-based study.

Diede L Loopik1, Ruud L M Bekkers2, Leon F A G Massuger3, Willem J G Melchers4, Albert G Siebers5, James Bentley6.   

Abstract

OBJECTIVE: In 2012, the joint clinical practice guideline from the Society of Obstetricians and Gynaecologists of Canada (SOGC) changed from immediate treatment to a more conservative management of Cervical Intraepithelial Neoplasia (CIN) grade 2 in young women. In this study, the outcomes before and after this management change were reviewed in Nova Scotia, Canada.
METHODS: A retrospective population-based cohort study was performed among women younger than 25 years with biopsy-proven CIN2, who were diagnosed in one of the colposcopy clinics in Nova Scotia between 2010 and 2014. Regression and progression rates were compared pre- and post-guideline changes.
RESULTS: Of the 636 women included in the study, 286 women were diagnosed with CIN2 before and 350 women after the management in Nova Scotia was changed. After implementation of the 2012 guidelines patients were more likely to receive conservative management (78.6% versus 44.1%; p < 0.001); which differs from the patients who underwent treatment during follow-up prior to the change in guidelines (73.4% versus 38.9%; p < 0.001). Regression occurred in 73.1% of all women, but women seen in the post-guideline change period had a higher regression rate and lower progression rate (p < 0.05). Histologic results from treatment specimen did not show a significant difference in low-grade or high-grade lesions before or after the guideline had been changed (p = 0.59).
CONCLUSION: Conservative management seems a safe and justified approach for women younger than 25 years with CIN2.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical intraepithelial neoplasia; Cohort study; Management; Observational study; Retrospective study; Young adult

Mesh:

Year:  2018        PMID: 30413339     DOI: 10.1016/j.ygyno.2018.10.038

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Patients with cervical intraepithelial neoplasms show different states of health-related quality of life and different coping styles depending on the choice of therapy: findings from the CIN study.

Authors:  Meike Schild-Suhren; Helge Ho Müller; Stephanie Klügel; Caroline Lücke; Aylin Mehren; Eduard Malik; Alexandra Philipsen
Journal:  Int J Womens Health       Date:  2019-09-12

2.  Comparison of Expectant and Excisional/Ablative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in the Era of HPV Testing.

Authors:  Kevin Dominique Tjandraprawira; Adeola Olaitan; Aviva Petrie; Nafisa Wilkinson; Adam N Rosenthal
Journal:  Obstet Gynecol Int       Date:  2022-03-24

3.  Blimp-1 is a prognostic indicator for progression of cervical intraepithelial neoplasia grade 2.

Authors:  Mayumi Saito; Aarthi Rajesh; Carrie Innes; Rachael van der Griend; Peter Fitzgerald; Bryony Simcock; Peter Sykes; Merilyn Hibma
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-06       Impact factor: 4.322

4.  Conservative management of women with cervical intraepithelial neoplasia grade 2 in Denmark: a cohort study.

Authors:  M Skorstengaard; E Lynge; J Suhr; G Napolitano
Journal:  BJOG       Date:  2020-01-22       Impact factor: 6.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.